Garrick C Stewart1, Amrut V Ambardekar2, Michelle M Kittleson3. 1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA, 02115, USA. gcstewart@bwh.harvard.edu. 2. Division of Cardiology, University of Colorado, Aurora, CO, USA. 3. Division of Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, USA.
Abstract
PURPOSE OF REVIEW: Extended survival with LVADs has generated interest in implantation for ambulatory patients with advanced heart failure (HF) prior to dependence on inotropes, though we remain limited in our ability to define and advance indications in this less sick advanced HF population. RECENT FINDINGS: The MedaMACS and ROADMAP studies have informed prognosis and decision-making for ambulatory patients with advanced HF. Sicker INTERMACS profiles are consistently associated with high risk of death or rescue LVAD. Appropriately selected patients in profile 4 should be considered for LVADs based on their high mortality and poor quality of life. These studies also shed light on discordant perceptions of HF disease severity between patients and their physicians. For ambulatory patients with HF not at imminent risk of death, shared decision-making about LVAD requires measured and individualized consideration of risk and benefit beyond survival. Future studies, including the ongoing REVIVAL study, should provide additional prognostic information in this patient population and should aid patients, caregivers, and physicians as they contemplate complex decisions regarding LVAD therapy.
PURPOSE OF REVIEW: Extended survival with LVADs has generated interest in implantation for ambulatory patients with advanced heart failure (HF) prior to dependence on inotropes, though we remain limited in our ability to define and advance indications in this less sick advanced HF population. RECENT FINDINGS: The MedaMACS and ROADMAP studies have informed prognosis and decision-making for ambulatory patients with advanced HF. Sicker INTERMACS profiles are consistently associated with high risk of death or rescue LVAD. Appropriately selected patients in profile 4 should be considered for LVADs based on their high mortality and poor quality of life. These studies also shed light on discordant perceptions of HF disease severity between patients and their physicians. For ambulatory patients with HF not at imminent risk of death, shared decision-making about LVAD requires measured and individualized consideration of risk and benefit beyond survival. Future studies, including the ongoing REVIVAL study, should provide additional prognostic information in this patient population and should aid patients, caregivers, and physicians as they contemplate complex decisions regarding LVAD therapy.
Authors: Josef Stehlik; Jerry D Estep; Craig H Selzman; Joseph G Rogers; John A Spertus; Keyur B Shah; Joyce Chuang; David J Farrar; Randall C Starling Journal: Circ Heart Fail Date: 2017-06 Impact factor: 8.790
Authors: Jerry D Estep; Randall C Starling; Douglas A Horstmanshof; Carmelo A Milano; Craig H Selzman; Keyur B Shah; Matthias Loebe; Nader Moazami; James W Long; Josef Stehlik; Vigneshwar Kasirajan; Donald C Haas; John B O'Connell; Andrew J Boyle; David J Farrar; Joseph G Rogers Journal: J Am Coll Cardiol Date: 2015-10-20 Impact factor: 24.094
Authors: James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel Journal: J Heart Lung Transplant Date: 2017-07-15 Impact factor: 10.247
Authors: Amrut V Ambardekar; Jennifer T Thibodeau; Adam D DeVore; Michelle M Kittleson; Rhondalyn C Forde-McLean; Maryse Palardy; Maria M Mountis; Linda Cadaret; Jeffrey J Teuteberg; Salpy V Pamboukian; Rongbing Xie; Lynne W Stevenson; Garrick C Stewart Journal: JACC Heart Fail Date: 2017-08-16 Impact factor: 12.035
Authors: Elisabet Zamora; Josep Lupón; Joan Vila; Agustín Urrutia; Marta de Antonio; Hèctor Sanz; Maria Grau; Jordi Ara; Antoni Bayés-Genís Journal: J Am Coll Cardiol Date: 2012-05-08 Impact factor: 24.094
Authors: James C Fang; Gregory A Ewald; Larry A Allen; Javed Butler; Cheryl A Westlake Canary; Monica Colvin-Adams; Michael G Dickinson; Phillip Levy; Wendy Gattis Stough; Nancy K Sweitzer; John R Teerlink; David J Whellan; Nancy M Albert; Rajan Krishnamani; Michael W Rich; Mary N Walsh; Mark R Bonnell; Peter E Carson; Michael C Chan; Daniel L Dries; Adrian F Hernandez; Ray E Hershberger; Stuart D Katz; Stephanie Moore; Jo E Rodgers; Joseph G Rogers; Amanda R Vest; Michael M Givertz Journal: J Card Fail Date: 2015-05-04 Impact factor: 5.712
Authors: James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Amrut V Ambardekar; Michelle M Kittleson; Maryse Palardy; Maria M Mountis; Rhondalyn C Forde-McLean; Adam D DeVore; Salpy V Pamboukian; Jennifer T Thibodeau; Jeffrey J Teuteberg; Linda Cadaret; Rongbing Xie; Wendy Taddei-Peters; David C Naftel; James K Kirklin; Lynne W Stevenson; Garrick C Stewart Journal: J Heart Lung Transplant Date: 2018-10-01 Impact factor: 10.247
Authors: Michelle M Kittleson; Amrut V Ambardekar; Lynne W Stevenson; Nisha A Gilotra; Palak Shah; Gregory A Ewald; Jennifer T Thibodeau; Josef Stehlik; Maryse Palardy; Jerry D Estep; Thomas M Cascino; J Timothy Baldwin; Neal Jeffries; Shokoufeh Khalatbari; Matheos Yosef; Wendy Taddei Peters; Blair Richards; Douglas L Mann; Keith D Aaronson; Garrick C Stewart Journal: J Heart Lung Transplant Date: 2021-09-16 Impact factor: 10.247